drugset / Trial / NCT02055352

Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD

NCT02055352

Phase 4 Completed 222 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

To demonstrate the free combination of budesonide and indacaterol is as efficacious as fluticasone and salmeterol in patients with COPD

Timeline

Start
2014-05-30
Primary completion
2016-01-26
Completion
2016-01-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 400 ug Inhaled
Subject Fluticasone Other / unclassified 250 ug Inhaled
Subject Indacaterol Other / unclassified 150 ug Inhaled
Subject Salmeterol Other / unclassified 50 ug Inhaled